Both resveratrol and ustekinumab induced the downregulation of HMGB1 expression, demonstrating a protective effect against DCM: Resveratrol prevented oxidative damage, myocardial fibrosis, and inflammation by inhibiting the HMGB1/RAGE/TLR4/NF-κB signaling pathway (15), whereas ustekin exerted a protective effect against DCM by reducing inflammation and cardiomyocyte apoptosis through inhibition of the JNK and p38 signaling pathways (16). Here, TLR4 is linked to familial dilated cardiomyopathy.